RxDoctor Payments Data

David Watson

Littleton, CONPI 1568420909

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 35.9% of the total. Reporting peaked in 2022 at $433 and has fallen 95.5% since, to $19 in 2024.

$1,729in general payments, 2019–2025

Across 101 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$620
  • Eisai Inc.$182
  • Mayne Pharma Commercial LLC$124
  • Bayer$92
  • Ascend Therapeutics US, LLC$86
  • Therapeuticsmd, Inc.$75
  • plus $550 from 18 others
$624,996in ownership & investment interests, 2019–2025

Across 2 payments — averaging $312,498 each. An ownership or investment interest held by the physician or an immediate family member.

  • Vektor Medical Inc.$625K

What the payments were for

  • Food & beverage$1,70599%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →